Filter Results:
(611)
Show Results For
- All HBS Web
(1,026)
- People (4)
- News (257)
- Research (611)
- Events (9)
- Multimedia (24)
- Faculty Publications (398)
Show Results For
- All HBS Web
(1,026)
- People (4)
- News (257)
- Research (611)
- Events (9)
- Multimedia (24)
- Faculty Publications (398)
Sort by
- 27 Jun 2005
- Research & Ideas
The Potential Downside of Win-Win
consideration for all managers. Value Creation—and Collusion Suppose that pharmaceutical firm A manufactures a new, beneficial drug and begins selling 100 million pills per year at $3.05 per pill. Each pill costs 5 cents to manufacture,... View Details
Keywords: by Max H. Bazerman
- 07 Apr 2003
- Research & Ideas
Three Steps for Crisis Prevention
South Africa over its attempt to reduce the cost of HIV drugs through parallel importation (buying pharmaceuticals in countries with lower prices and then importing them) and compulsory licensing (requiring patent holders to allow others... View Details
Keywords: by Michael D. Watkins & Max H. Bazerman
- 02 Jan 2020
- Op-Ed
Medicare for All or Public Option: Can Either Heal Health Care?
for All published by the Harvard Business Review. [Image: Hispanolistic] Related Reading Germany May Have the Answer for Reducing Drug Prices What Hospitals Must Learn to Compete Making Health Insurance That Consumers Actually Like What... View Details
- 30 Mar 2010
- First Look
First Look: March 30
regulatory objections were debated and tensions rose between U.S. and EC regulators. Purchase this case:http://cb.hbsp.harvard.edu/cb/product/310086-PDF-ENG Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and... View Details
Keywords: Sean Silverthorne
- 16 Oct 2013
- Op-Ed
Response to Readers: Combating Climate Change with Nuclear Power and Fracking
recommendations in my mind to improve the pace of nuclear innovation. A clear direction for improvement would be to adopt a Food and Drug Administration-style drug development type regulatory model with... View Details
- 11 Oct 2006
- Research & Ideas
The Success of Reverse Leveraged Buyouts
business press and savvy business experts such Warren Buffett. It didn’t help when one of the most publicized RLBOs—Refco—collapsed in 2005 shortly after its initial public offering. And on September 21, a 70-million share offering for View Details
- 12 Jul 2020
- Research & Ideas
Solving COVID'S Mental Health Crisis
for everyone and also highlighted the important link between research, discovery, and cure." The GPP is a statewide prevention program aimed at reducing the use of dangerous drugs among teens and young adults through awareness campaigns,... View Details
- 14 Apr 2021
- Research & Ideas
The High Cost of the Slow COVID Vaccine Rollout
the United States, the Federal Drug Administration this week advised states to pause the use of the Johnson & Johnson vaccine after six women developed a rare blood-clotting disorder, raising new concerns about total vaccine supply.... View Details
- 26 Sep 2006
- First Look
First Look: September 26, 2006
the pandemic. Most have not been very successful. An examination of three strategies for distributing antiretroviral drugs (ARVs) to patients in three countries on three continents, Africa, Asia, and South America, suggests a customer... View Details
Keywords: Sean Silverthorne
- 27 Sep 2011
- First Look
First Look: September 27
Even in the absence of national health coverage, the United States became the world's largest prescription drug market and emerged as the global leader in new drug research and testing. With health benefits... View Details
Keywords: Sean Silverthorne
- 19 Nov 2014
- HBS Case
Marketing Marijuana
something that hadn't been done in 81 years—make an illegal drug legal. “They do not need to buy it at a fancy store—they'll go to a back alley basement shop as long as the product delivers” Of course, the question remains: How will state... View Details
- 05 Jul 2004
- Research & Ideas
Radical Change, Entrepreneurial Opportunity
tightly coupled relationships with customers to engage in trials of different product concepts, producers and users can jointly learn about and make sense of the new technology. For instance, Surface Logix, a firm with highly sophisticated, flexible technology called... View Details
- 23 Mar 2010
- First Look
First Look: March 23
Publications "From Visible Harm to Relative Risk: Centralization and Fragmentation of Pharmacovigilance Author: Arthur A. Daemmrich Publication: Chap. 13 in The Fragmentation of U.S. Health Care, Oxford University Press, 2010 Abstract Adverse View Details
Keywords: Martha Lagace
- 26 Apr 2004
- Research & Ideas
A Clear Eye for Innovation
series of contact-lens products, introduced a drug for treating age-related macular degeneration, pioneered a new lens-manufacturing process that dramatically reduced production costs, and overtook J&J in some market segments. The... View Details
- 15 Feb 2000
- Lessons from the Classroom
Delivering Information Services: A 30-Year Perspective
IPO in 1990 to a $10-billion company today, with a market value of close to $140 billion! I'm also doing research for a case on Drugstore.com, which is essentially a drug store "built" on the Internet. It's getting ready to... View Details
Keywords: by Staff
- 28 Jul 2009
- First Look
First Look: July 28
report, new CEO Hank McKinnell discusses Pfizer's performance goals and its acquisition of Pharmacia, which gave it control of the anti-arthritis drug Celebrex. In the 2005 report, McKinnell discusses his decision to keep Celebrex on the... View Details
Keywords: Martha Lagace
- 18 Aug 2011
- Lessons from the Classroom
Business Plan Contest: 15 Years of Building Better Entrepreneurs
in 2001 with Alec Machiels (MBA '01) at the helm, its plan hinged on a mechanism created by a team of Harvard and MIT scientists that used atomic force microscopy in drug research. "A number of the scientists decided that being part of a... View Details
- 08 Apr 2009
- Research & Ideas
Clayton Christensen on Disrupting Health Care
screening participants in drug trials and make it possible to track and troubleshoot unexpected problems that show up after a drug is introduced into the general population, like what happened with Vioxx.... View Details
- 07 Aug 2006
- Research & Ideas
Whatever Happened to Caveat Emptor?
basic material needs to concerns about the safety and quality of these products. When products did fail—as happened dramatically in the late 1950s with the antinausea drug Thalidomide—such cases became the focus of aggressive consumer... View Details
- 28 Oct 2014
- First Look
First Look: October 28
disruptive to its drug development efforts and delay new drugs coming to market. UK politicians expressed concerns over downsizing and job losses in the economically important pharmaceutical sector. The case... View Details
Keywords: Carmen Nobel